Smet, P.A.G.M. de

patient study cyp 2c variant genotype complication allele anticoagulant acenocoumarol event therapy cyp 2c polymorphisms cyp 2c allele 100 treatment-years variant genotype phenprocoumon rotterdam treatment polymorphism cyp 2c genotype anticoagulant therapy rotterdam study initiation phase coumarin cohort hazard ratios anticoagulation type genotype cyp 2c alleles hazard warfarin initiation treatment-year study period variant alleles cytochrome variant allele ratio inr ≥ 6.0 phase effect population netherland carrier frequency analysis erasmus mc anticoagulation clinic hemorrhage coumarin anticoagulants difference metabolism hospital rosendaal fr 100 treatmentyears allelic target visser number target inr level van der meer anticoagulant treatment level period variant genotypes enzyme 90 days study population clinic dosing erasmu pharmacogenetic table association factor death 6.0 dose adjustment hazard ratio episode